{"data":{"id":"us/38-cfr-4.79","jurisdiction":"us","citation":"38 CFR 4.79","heading":"Schedule of ratings—eye.","body":"Diseases of the Eye\nRating\nGeneral Rating Formula for Diseases of the Eye:\nEvaluate on the basis of either visual impairment due to the particular condition or on incapacitating episodes, whichever results in a higher evaluation\nWith documented incapacitating episodes requiring 7 or more treatment visits for an eye condition during the past 12 months 60\nWith documented incapacitating episodes requiring at least 5 but less than 7 treatment visits for an eye condition during the past 12 months 40\nWith documented incapacitating episodes requiring at least 3 but less than 5 treatment visits for an eye condition during the past 12 months 20\nWith documented incapacitating episodes requiring at least 1 but less than 3 treatment visits for an eye condition during the past 12 months 10\nNote (1): For the purposes of evaluation under 38 CFR 4.79, an incapacitating episode is an eye condition severe enough to require a clinic visit to a provider specifically for treatment purposes\nNote (2): Examples of treatment may include but are not limited to: Systemic immunosuppressants or biologic agents; intravitreal or periocular injections; laser treatments; or other surgical interventions\nNote (3): For the purposes of evaluating visual impairment due to the particular condition, refer to 38 CFR 4.75-4.78 and to § 4.79, diagnostic codes 6061-6091\n6000 Choroidopathy, including uveitis, iritis, cyclitis, or choroiditis.\n6001 Keratopathy.\n6002 Scleritis.\n6006 Retinopathy or maculopathy not otherwise specified\n6007 Intraocular hemorrhage.\n6008 Detachment of retina.\n6009 Unhealed eye injury.\nNote: This code includes orbital trauma, as well as penetrating or non-penetrating eye injury\n6010 Tuberculosis of eye:\nActive 100\nInactive: Evaluate under § 4.88c or § 4.89 of this part, whichever is appropriate\n6011 Retinal scars, atrophy, or irregularities:\nLocalized scars, atrophy, or irregularities of the retina, unilateral or bilateral, that are centrally located and that result in an irregular, duplicated, enlarged, or diminished image 10\nAlternatively, evaluate based on the General Rating Formula for Diseases of the Eye, if this would result in a higher evaluation\n6012 Angle-closure glaucoma\nEvaluate under the General Rating Formula for Diseases of the Eye. Minimum evaluation if continuous medication is required 10\n6013 Open-angle glaucoma\nEvaluate under the General Rating Formula for Diseases of the Eye. Minimum evaluation if continuous medication is required 10\n6014 Malignant neoplasms of the eye, orbit, and adnexa (excluding skin):\nMalignant neoplasms of the eye, orbit, and adnexa (excluding skin) that require therapy that is comparable to those used for systemic malignancies, i.e., systemic chemotherapy, X-ray therapy more extensive than to the area of the eye, or surgery more extensive than enucleation 100\nNote: Continue the 100 percent rating beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy, or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating will be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination will be subject to the provisions of § 3.105(e) of this chapter. If there has been no local recurrence or metastasis, evaluate based on residuals\nMalignant neoplasms of the eye, orbit, and adnexa (excluding skin) that do not require therapy comparable to that for systemic malignancies:\nSeparately evaluate visual and nonvisual impairment, e.g., disfigurement (diagnostic code 7800), and combine the evaluations\n6015 Benign neoplasms of the eye, orbit, and adnexa (excluding skin):\nSeparately evaluate visual and nonvisual impairment, e.g., disfigurement (diagnostic code 7800), and combine the evaluations\n6016 Nystagmus, central 10\n6017 Trachomatous conjunctivitis:\nActive: Evaluate under the General Rating Formula for Diseases of the Eye, minimum rating 30\nInactive: Evaluate based on residuals, such as visual impairment and disfigurement (diagnostic code 7800)\n6018 Chronic conjunctivitis (nontrachomatous):\nActive: Evaluate under the General Rating Formula for Diseases of the Eye, minimum rating 10\nInactive: Evaluate based on residuals, such as visual impairment and disfigurement (diagnostic code 7800)\n6019 Ptosis, unilateral or bilateral:\nEvaluate based on visual impairment or, in the absence of visual impairment, on disfigurement (diagnostic code 7800).\n6020 Ectropion:\nBilateral 20\nUnilateral 10\n6021 Entropion:\nBilateral 20\nUnilateral 10\n6022 Lagophthalmos:\nBilateral 20\nUnilateral 10\n6023 Loss of eyebrows, complete, unilateral or bilateral 10\n6024 Loss of eyelashes, complete, unilateral or bilateral 10\n6025 Disorders of the lacrimal apparatus (epiphora, dacryocystitis, etc.):\nBilateral 20\nUnilateral 10\n6026 Optic neuropathy\n6027 Cataract:\nPreoperative: Evaluate under the General Rating Formula for Diseases of the Eye\nPostoperative: If a replacement lens is present (pseudophakia), evaluate under the General Rating Formula for Diseases of the Eye. If there is no replacement lens, evaluate based on aphakia (diagnostic code 6029)\n6029 Aphakia or dislocation of crystalline lens:\nEvaluate based on visual impairment, and elevate the resulting level of visual impairment one step.\nMinimum (unilateral or bilateral) 30\n6030 Paralysis of accommodation (due to neuropathy of the Oculomotor Nerve (cranial nerve III)). 20\n6032 Loss of eyelids, partial or complete:\nSeparately evaluate both visual impairment due to eyelid loss and nonvisual impairment, e.g., disfigurement (diagnostic code 7800), and combine the evaluations.\n6034 Pterygium:\nEvaluate under the General Rating Formula for Diseases of the Eye, disfigurement (diagnostic code 7800), conjunctivitis (diagnostic code 6018), etc., depending on the particular findings, and combine in accordance with § 4.25\n6035 Keratoconus\n6036 Status post corneal transplant:\nEvaluate under the General Rating Formula for Diseases of the Eye. Minimum, if there is pain, photophobia, and glare sensitivity 10\n6037 Pinguecula:\nEvaluate based on disfigurement (diagnostic code 7800).\n6040 Diabetic retinopathy\n6042 Retinal dystrophy (including retinitis pigmentosa, wet or dry macular degeneration, early-onset macular degeneration, rod and/or cone dystrophy)\n6046 Post-chiasmal disorders\nImpairment of Central Visual Acuity\n6061 Anatomical loss of both eyes 1 100\n6062 No more than light perception in both eyes 1 100\n6063 Anatomical loss of one eye: 1\nIn the other eye 5/200 (1.5/60) 100\nIn the other eye 10/200 (3/60) 90\nIn the other eye 15/200 (4.5/60) 80\nIn the other eye 20/200 (6/60) 70\nIn the other eye 20/100 (6/30) 60\nIn the other eye 20/70 (6/21) 60\nIn the other eye 20/50 (6/15) 50\nIn the other eye 20/40 (6/12) 40\n6064 No more than light perception in one eye: 1\nIn the other eye 5/200 (1.5/60) 100\nIn the other eye 10/200 (3/60) 90\nIn the other eye 15/200 (4.5/60) 80\nIn the other eye 20/200 (6/60) 70\nIn the other eye 20/100 (6/30) 60\nIn the other eye 20/70 (6/21) 50\nIn the other eye 20/50 (6/15) 40\nIn the other eye 20/40 (6/12) 30\n6065 Vision in one eye 5/200 (1.5/60):\nIn the other eye 5/200 (1.5/60) 1 100\nIn the other eye 10/200 (3/60) 90\nIn the other eye 15/200 (4.5/60) 80\nIn the other eye 20/200 (6/60) 70\nIn the other eye 20/100 (6/30) 60\nIn the other eye 20/70 (6/21) 50\nIn the other eye 20/50 (6/15) 40\nIn the other eye 20/40 (6/12) 30\n6066 Visual acuity in one eye 10/200 (3/60) or better:\nVision in one eye 10/200 (3/60):\nIn the other eye 10/200 (3/60) 90\nIn the other eye 15/200 (4.5/60) 80\nIn the other eye 20/200 (6/60) 70\nIn the other eye 20/100 (6/30) 60\nIn the other eye 20/70 (6/21) 50\nIn the other eye 20/50 (6/15) 40\nIn the other eye 20/40 (6/12) 30\nVision in one eye 15/200 (4.5/60):\nIn the other eye 15/200 (4.5/60) 80\nIn the other eye 20/200 (6/60) 70\nIn the other eye 20/100 (6/30) 60\nIn the other eye 20/70 (6/21) 40\nIn the other eye 20/50 (6/15) 30\nIn the other eye 20/40 (6/12) 20\nVision in one eye 20/200 (6/60):\nIn the other eye 20/200 (6/60) 70\nIn the other eye 20/100 (6/30) 60\nIn the other eye 20/70 (6/21) 40\nIn the other eye 20/50 (6/15) 30\nIn the other eye 20/40 (6/12) 20\nVision in one eye 20/100 (6/30):\nIn the other eye 20/100 (6/30) 50\nIn the other eye 20/70 (6/21) 30\nIn the other eye 20/50 (6/15) 20\nIn the other eye 20/40 (6/12) 10\nVision in one eye 20/70 (6/21):\nIn the other eye 20/70 (6/21) 30\nIn the other eye 20/50 (6/15) 20\nIn the other eye 20/40 (6/12) 10\nVision in one eye 20/50 (6/15):\nIn the other eye 20/50 (6/15) 10\nIn the other eye 20/40 (6/12) 10\nVision in one eye 20/40 (6/12):\nIn the other eye 20/40 (6/12) 0\n1 Review for entitlement to special monthly compensation under 38 CFR 3.350.\nRatings for Impairment of Visual Fields\nRating\n6080 Visual field defects:\nHomonymous hemianopsia 30\nLoss of temporal half of visual field:\nBilateral 30\nUnilateral 10\nOr evaluate each affected eye as 20/70 (6/21)\nLoss of nasal half of visual field:\nBilateral 10\nUnilateral 10\nOr evaluate each affected eye as 20/50 (6/15)\nLoss of inferior half of visual field:\nBilateral 30\nUnilateral 10\nOr evaluate each affected eye as 20/70 (6/21)\nLoss of superior half of visual field:\nBilateral 10\nUnilateral 10\nOr evaluate each affected eye as 20/50 (6/15)\nConcentric contraction of visual field:\nWith remaining field of 5 degrees: 1\nBilateral 100\nUnilateral 30\nOr evaluate each affected eye as 5/200 (1.5/60)\nWith remaining field of 6 to 15 degrees:\nBilateral 70\nUnilateral 20\nOr evaluate each affected eye as 20/200 (6/60)\nWith remaining field of 16 to 30 degrees:\nBilateral 50\nUnilateral 10\nOr evaluate each affected eye as 20/100 (6/30)\nWith remaining field of 31 to 45 degrees:\nBilateral 30\nUnilateral 10\nOr evaluate each affected eye as 20/70 (6/21)\nWith remaining field of 46 to 60 degrees:\nBilateral 10\nUnilateral 10\nOr evaluate each affected eye as 20/50 (6/15)\n6081 Scotoma, unilateral:\nMinimum, with scotoma affecting at least one-quarter of the visual field (quadrantanopsia) or with centrally located scotoma of any size 10\nAlternatively, evaluate based on visual impairment due to scotoma, if that would result in a higher evaluation\n1 Review for entitlement to special monthly compensation under 38 CFR 3.350.\nRatings for Impairment of Muscle Function\nDegree of diplopia Equivalent visual acuity\n6090 Diplopia (double vision):\n(a) Central 20 degrees 5/200 (1.5/60)\n(b) 21 degrees to 30 degrees\n(1) Down 15/200 (4.5/60)\n(2) Lateral 20/100 (6/30)\n(3) Up 20/70 (6/21)\n(c) 31 degrees to 40 degrees\n(1) Down 20/200 (6/60)\n(2) Lateral 20/70 (6/21)\n(3) Up 20/40 (6/12)\nNote: In accordance with 38 CFR 4.31, diplopia that is occasional or that is correctable with spectacles is evaluated at 0 percent.\n6091 Symblepharon:\nEvaluate under the General Rating Formula for Diseases of the Eye, lagophthalmos (diagnostic code 6022), disfigurement (diagnostic code 7800), etc., depending on the particular findings, and combine in accordance with § 4.25","path":["Title 38—Pensions, Bonuses, and Veterans' Relief","CHAPTER I—DEPARTMENT OF VETERANS AFFAIRS","PART 4—SCHEDULE FOR RATING DISABILITIES","Subpart B—Disability Ratings"],"source_url":"https://www.ecfr.gov/api/versioner/v1/full/2026-08-25/title-38.xml","current_through":"2026-08-25","vintage":"","retrieved_at":"2026-08-27T02:25:50Z","sha256":"f8890b591c209780244e0e57f33feffd91a5a122d3faa22a192ab3186984a370","source_id":"us-cfr","stale":true,"prev":"us/38-cfr-4.78","next":"us/38-cfr-4.80-4.84"},"notice":"GroundRules: Original legal text. Not legal advice."}